Τόμος 21 (2007) – Τεύχος 3 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 21 (2007) – Issue 3 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Reproductive Molecular Research Group.

1.      Department of Obstetrics and Gynaecology, University of Cambridge, Cambridge, CB2 2SW, United Kingdom

2.     Department of Pathology, University of Cambridge, Cambridge, CB2 1QP, United Kingdom

pharmakonpress[at]pharmakonpress[.]gr

2. Knuutila S., Bjorkqvist A.-M., Autio K., et al.: DNA copy number amplifications in human neoplasms – a review of comparative genomic hybridization studies. Am.  J. Pathol. 152: 1107-1123 (1998)

3. Glinsky G., Krones-Herzig A., Glinskii A.: Malignancy-associated regions of transcriptional activation: gene expression profiling identifies common chromosomal regions of a recurrent transcriptional activation in human prostate, breast, ovarian, and colon cancers. Neoplasia 5: 218-228 (2003)

4. Glinsky G., Ivanova Y., Glinskii A.: Common malignancy-associated regions of transcriptional activation (MARTA) in human prostate, breast, ovarian, and colon cancers are targets for DNA amplification. Cancer Lett. 201: 67-77 (2003)

5. Yotov W.V., Harnel H., Rivard G.-E., et al.: Amplifications of DNA primase 1 (PRIM1) in human osteosarcomas. Genes Chromosomes Cancer 26: 62-69 (1999)

6. Su Y., Trent J., Guan X.-Y., Meltzer P.: Direct isolation of genes encoded within a homogeneously staining region by chromosome microdissection. Proc. Natl. Acad. Sci. USA 91: 9121-9125 (1994)

7. Su Y., Hutter C., Trent J., Meltzer P.: Complete sequence analysis of a gene (OS-9) ubiquitously expressed in human tissues and amplified in sarcomas. Mol. Carcinog. 15: 270-275 (1996)

8. Kimura Y., Nakazawa M., Yamada M.: Cloning and characterization of three isoforms of OS-9 cDNA and expression of the OS-9 gene in various human tumor cell lines. J. Biochem. 123: 876-882 (1998)

9. Litovchick L., Friedmann E., Shaltiel S.: A selective interaction between OS-9 and the carboxyl-terminal tail of meprin beta. J. Biol. Chem. 277: 34413-34423 (2002)

10. Friedmann E., Salzberg Y., Weinberger A., Shaltiel S., Gerst J.: YOS9, the putative yeast homolog of a gene amplified in osteosarcomas, is involved in the Endoplasmic Reticulum(ER)-Golgi transport of GPI-anchored proteins. J. Biol. Chem. 277: 35274-35281 (2002)

11. Kimura Y., Nakazawa M., Tsuchiya N., Asakawa S., Shimizu N., Yamada M.: Genomic organization of the OS-9 gene amplified in human sarcomas. J. Biochem. (Tokyo) 122: 1190-1195 (1997)

12. Nakayama T., Yaio T., Kuwajima G., Yoshie O., Sa- kata T.: Ca²⁺-dependent interaction of N-copine, a member of the two C2 domain protein family, with OS-9, the product of a gene frequently amplified in osteosarcoma. FEBS Lett. 453: 77-80 (1999)

13. Elkahloun A., Bittner M., Hoskins K., Gemmill R., Meltzer P.: Molecula cytogenetic characterization and physical mapping of 12q13-15 amplification in human cancers. Genes Chromosomes Cancer 17: 205-214 (1996)

14. Gracia E., Fischer U., ElKahloun A., Trent J.M., Meese E., Meltzer P.S.: Isolation of genes amplified in human cancers by microdissection mediated cDNA capture. Human Molecular Genetics 5: 595-600 (1996)

15. Vigneron N., Ooms A., Morel S., Degiovanni G., Eynde B.V.d.: Identification of a new peptide recodnized by autologous cytolytic T lymphocytes on a human melanoma. Cancer lmmun. 2: 9 (2002)

16. Jaffe E., Nachman R., Becker C., Minick C.: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. lnvest. 52: 2745-2756 (1973)

17. Dexter T., Garland J., Scott D., Scolnick E., Metcalf D.: Growth of factor-dependent hemopoietic precursor cell lines. J. Exp. Med. 152: 1036-1047 (1980)

18. Itoh N., Tsujimoto Y., Nagata S.: Effect of bcl-2 on Fas antigen-mediated cell death. J. lmmunol. 151: 621- 627 (1993)

19. Vaux D.L., Weissman I.L.: Neither macromolecular sythesis nor Myc is required for cell death via the mechanism that can be controlled by Bcl-2. Mol. Cell. Biol. 13: 7000-7005 (1993)

20. Deng X., Ruvolo P., Carr B., May W.S.,Jr: Survival function of ERK1/2 and IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc. Natl. Acad. Sci. USA 97: 1578-1583 (2000)

21. Chandele A., Prasad V., Jagtap J., Shukla R., Shas- try P.: Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 6: 29-40 (2004)

22. Cummings B., Kinsey G., Bolchoz L., Schnellmann R.: Identification of a caspase-independent apoptosis in epithelial and cancer cells. J. Pharmacol. Exp. Ther. 310(1): 126-134 (2004)

23. Giuliano M., Bellavia G., Lauricella M., et al.: Staurosporine-induced apoptosis in Chang liver cells is associated with down-regulation of Bcl-2 and Bcl-XL. lnt. J. Mol. Med. 13: 565-571 (2004)

24. Zhang X., Gillespie S., Hersey P.: Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent pathways. Mol. Cancer Ther. 3: 187-197 (2004)

25. Varfolomeev E.E., Ashkenazi A.: Tumor necrosis factor:  an apoptosis JuNKie? Cell 116: 491-497 (2004)

26. Huang D.C.S., O’Reilly L.A., Strasser A., Cory S.: The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J. 16: 4628-4638 (1997)

27. Huang D.C.S., Adams J.M., Cory S.: The conserved N-terminal BH4 dopamin of Bcl-2 homologues is essential for inhibition  of  apoptosis  and  interaction with CED-4.EMBO J. 17: 1029-1039 (1998)

28. Johnson D.: Regulation of survival pathways by IL-3 and induction of apoptosis following IL-3 withdrawl. Front. Biosci. 3: d313-d324 (1998)

29. May W., Tyler P., Ito T., Armstrong D., Qatha K., Davidson N.: Interleukin-3 and bryostatin-1 mediate hyperpohosphorylation of BCL2alpha in association with suppression of apoptosis. J. Biol. Chem. 269: (26865- 26870) (1994)

30. Baek J.H., Mahon P.C., Oh J., Kelly B., Krishnamachary B., Pearson M., Chan D.A., Giaccia A.J., Semenza G.L.: OS-9 interacts  with  Hypoxia-Inducible Factor 1a and propyl hydroxylases to promote oxygen- dependent degradation of HIF-1a. Mol. Cell 17: 503-512 (2005)

31. Kim H.M., Yeo E.J., Chun Y.S., Park J.W.: A domain responsible for HIF-1a degradation by YC-1, a novel anti-cancer agent. lnt. J. Oncol.  29: 255-260 (2006)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr